PreciThera develops innovative biological therapeutics targeting orphan bone diseases that cannot be treated via traditional protein replacement therapies. The company combines informatics-based tools, integrating RNA sequencing with genomic and clinical databases, to validate the major pathways responsible for clinical symptoms in rare genetic disorders. Its pipeline focuses on novel molecules with a lead candidate intended to be advanced through IND-enabling work and into clinical studies. PreciThera intends to use the Series A proceeds to develop additional molecules, establish clinical proof of concept for the lead candidate and identify a path to registration. The company was co-founded in 2016 by Dr. Philippe Crine and Dr. Susan Schiavi and is led by CEO Pierre Beauparlant. It is based in Montreal, Canada.

Total raised

$29M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2017